Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
VolitionRx Limited (VNRX): Blood-Based Diagnostics for Cancer and Sepsis

VolitionRx Limited (VNRX): Blood-Based Diagnostics for Cancer and Sepsis

Key Takeaways

  • VNRX is the stock ticker for VolitionRx Limited, a multinational epigenetics company developing simple, low-cost blood tests for cancer and diseases linked to NETosis, such as sepsis.
  • The company's technology is built on its Nu.Q platform, which measures nucleosomes in blood as biomarkers of disease.
  • VolitionRx operates across several product pillars, including veterinary cancer screening (Nu.Q Vet), sepsis detection (Nu.Q NETs), and human cancer testing (Nu.Q Cancer).
  • The business is early-stage and development-focused, generating modest revenue while reporting net losses, and its auditors have noted substantial doubt about its ability to continue as a going concern.
  • VolitionRx is headquartered in Henderson, Nevada, with additional operations in Europe and Asia, and is listed on the NYSE American exchange.

Introduction

VolitionRx Limited is a clinical-stage life sciences company centered on a straightforward concept: using a standard blood sample to detect and track serious diseases. The firm develops diagnostic tests rooted in Nucleosomics, which focuses on identifying and measuring nucleosomes—basic units of DNA in the bloodstream and other fluids—as signs that disease may be present. Investors track VNRX because the company targets major unmet needs in cancer and sepsis diagnostics with tests positioned as simple, affordable, and straightforward to implement.

Company Overview

VolitionRx Limited was established in 1998 and is based in Henderson, Nevada, with research, production, and commercial activities across Belgium, the United Kingdom, the United States, and Singapore. It is led by President and Group Chief Executive Officer Cameron Reynolds, who also founded the company. VNRX trades on the NYSE American exchange.

The core technology rests on the Nu.Q platform, which identifies and quantifies nucleosomes in blood samples. This supports a range of product areas:

  • Nu.Q Vet — a cancer screening test for companion animals such as dogs and cats, already available commercially in several countries.
  • Nu.Q NETs — a test for conditions tied to NETosis, an immune response associated with issues like sepsis.
  • Nu.Q Cancer — blood tests for detecting, monitoring, and assessing treatment response in human cancers.
  • Nu.Q Discover — a nucleosome-profiling tool for researchers and drug developers.
  • Capture-PCR and Capture-Seq — methods for isolating circulating tumor-derived DNA from plasma for early cancer detection.

The business approach emphasizes commercialization through direct efforts and licensing and distribution partnerships. Rather than constructing extensive sales and lab infrastructure independently, the company works with larger diagnostic and animal-health firms. Revenue comes mainly from product sales, services, and potential milestone or licensing payments. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. The financial picture remains that of an early-stage developer, with relatively modest revenue against ongoing operating expenses.

Why Investors Follow VNRX

Attention centers on the sizable addressable markets and the platform-based approach to diagnostics. Cancer and sepsis rank among leading global causes of death, and the company views its technology as a low-cost, accessible option for earlier detection. It points to multi-billion-dollar total addressable markets spanning its product areas, from companion-animal screening to human liquid biopsy and multi-cancer early detection.

A central part of the thesis is the adaptability of the Nu.Q platform. One underlying technology applies across veterinary health, sepsis monitoring, and oncology, allowing research to support multiple commercial paths. The licensing strategy supports market reach by teaming with established diagnostic and liquid-biopsy partners that already maintain labs, analyzers, and sales networks, helping avoid the full burden of commercialization costs.

Reported progress includes CE-marked availability of the Nu.Q NETs test in Europe and government-supported clinical programs for sepsis detection. Ongoing work to obtain reimbursement for cancer tests in European markets adds to the longer-term drivers under review.

Risks and Important Considerations

Investing in VolitionRx involves notable risks common to early-stage life sciences firms. The company has posted ongoing net losses and an accumulated deficit, and its auditors have issued a going-concern opinion highlighting substantial doubt about continuing operations without additional capital. This underscores reliance on further financing, licensing arrangements, or grants to support research, trials, and commercialization.

Additional factors include:

  • Regulatory and reimbursement risk — diagnostic tests face strict regulatory requirements and, for broader use, must secure payer reimbursement. Setbacks in either can constrain commercialization.
  • Competition — diagnostics and liquid-biopsy fields include many larger, better-funded players pursuing similar objectives in cancer detection and sepsis monitoring.
  • Dilution and capital needs — reliance on equity offerings and convertible debt can dilute shareholders and bring financial covenants.
  • Listing compliance — the company has received notices on NYSE American standards and continues efforts to maintain compliance.
  • Execution risk — the shift from research and development to wider commercialization remains underway, with future revenue tied to licensing success and clinical adoption.

Conclusion

VolitionRx Limited stands out as an epigenetics company working to introduce straightforward blood-based diagnostics for major medical challenges such as cancer and sepsis. Its Nu.Q platform and partnership-focused model provide a distinct path into markets with meaningful long-term potential. At the same time, the company is still early in commercialization, with modest revenue, continued losses, and notable capital needs. For investors, VNRX offers a high-risk, high-uncertainty position in the diagnostics and liquid-biopsy space, best viewed as a speculative holding rather than a mature, cash-generating business.

Using Tickeron’s AI Screener

In my research process, I occasionally use Tickeron’s AI Screener to scan for stocks that align with specific technical, fundamental, or industry criteria. It allows efficient comparison across thousands of names using customizable filters and AI signals, which can help surface ideas that fit a given strategy without reviewing each company individually.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: VNRX

VNRX in +5.82% Uptrend, growing for three consecutive days on November 09, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where VNRX advanced for three days, in 146 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where VNRX's RSI Indicator exited the oversold zone, 23 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 64%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 46 cases where VNRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VNRX as a result. In 90 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

VNRX moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VNRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

VNRX broke above its upper Bollinger Band on November 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for VNRX entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.183) is normal, around the industry mean (4.142). P/E Ratio (-0.051) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.767) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating fairly steady price growth. VNRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VNRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -9%. For the same Industry, the average monthly price growth was -9%, and the average quarterly price growth was -14%. POAS experienced the highest price growth at 172%, while LFWD experienced the biggest fall at -46%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -44%. For the same stocks of the Industry, the average monthly volume growth was -3% and the average quarterly volume growth was -49%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 62
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 14 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a development stage life sciences company

Industry MedicalNursingServices

Industry
Medical Or Nursing Services
Address
1489 West Warm Springs Road
Phone
+1 512 774-8930
Employees
75
Web
https://www.volition.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.